Molecular analysis of the Na+ channel blocking actions of the novel class I anti-arrhythmic agent RSD 921

British Journal of Pharmacology

Volumn 127, Issue 1, 1999, Pages 9-18

  Pugsley, Michael K ^a,b   Goldin, Alan L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b XOMA Corporation   (United States)

Author keywords

Arylbenzacetamide; Class I anti arrhythmic; Na+ channel; RSD 921; Xenopus oocytes

Indexed keywords

ACETAMIDE DERIVATIVE; ANTIARRHYTHMIC AGENT; LOCAL ANESTHETIC AGENT; MUTANT PROTEIN; N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZO[B]THIOPHENE 4 ACETAMIDE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; HEART MUSCLE; HYPERPOLARIZATION; NERVE CELL; NONHUMAN; OOCYTE; PRIORITY JOURNAL; SKELETAL MUSCLE; VOLTAGE CLAMP; XENOPUS LAEVIS;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ELECTRIC STIMULATION; ION CHANNEL GATING; MUSCLE, SKELETAL; MUTATION; MYOCARDIUM; NEURONS; OOCYTES; PATCH-CLAMP TECHNIQUES; PYRROLES; RATS; RNA; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; THIOPHENES; TRANSCRIPTION, GENETIC; XENOPUS LAEVIS;

EID: 0032902805     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702488     Document Type: Article

References (45)

1. Armstrong, C.M., Benzanilla, F. & Rojas, E. (1973). Destruction of sodium conductance inactivation of squid axons perfused with pronase. J. Gen. Physiol., 62, 375-391.
2. Auld, V.J., Goldin, A.L., Krafte, D.S., Catterall, W.A., Lester, H.A., Davidson, N. & Dunn, R.J. (1990). A neutral amino acid change in segment IIS4 dramatically alters the gating properties of the voltage-dependent sodium channel. Proc. Natl. Acad. Sci. U.S.A., 87, 323-327.
3. Bailey, J.C. (1981). The electrophysiological basis for cardiac electrical activity: normal and abnormal. Heart Lung, 10, 455-464.
4. Bain, A.I., Barrett, T.D., Beatch, G.N., Fedida, D., Hayes, E.S., Plouvier, B., Pugsley, M.K., Walker, M.J.A., Walker, M.L., Wall, R.A., Yong, S.L. & Zolotoy, A. (1997). Better antiarrhythmics? Development of antiarrhythmic drugs selective for ischaemia-dependent arrhythmias. Drug Dev. Res., 42, 198-210.
5. Barrett, T.D., Macleod, B.A. & Walker, M.J.A. (1997). A model of myocardial ischaemia for the simultaneous assessment of electrophysiological changes and arrhythmias in intact rabbits. J. Pharmacol. Tox. Meth., 37, 27-36.
6. Bean, B.P., Cohen, C.J. & Tsien, R.W. (1983). Lidocaine block of cardiac sodium channels. J. Gen. Physiol., 81, 613-642.
7. Beatch, G.N., Macleod, B.A., Pugsley, M.K. & Walker, M.J.A. (1997). RSD 921, a potent new local anesthetic. ASEAN Cong. Anesthesiol., 60.
8. + channel. Modification of block by alterations in the α-subunit III-IV interdomain. Circ. Res., 77, 584-592.
9. Cahalan, M.D. (1978). Local anesthetic block of sodium channels in normal and pronase-treated squid giant axons. Biophys. J., 23, 285-311.
10. Cascio, W.E., Johnson, T.A. & Gettes, L.S. (1995). Electrophysiologic changes in ischemic ventricular myocardium: I. Influence of ionic, metabolic, and energetic changes. J. Cardiovasc. Electrophysiol., 6, 1039-1062.
11. Clark, C.R., Birchmore, B., Sharif, N.A., Hunter, J.C., Hill, R.G. & Hughes, J. (1988a). DD117302: A selective agonist for the κ-opioid receptor. Br. J. Pharmacol., 93, 618-626.
12. Clark, C.R., Halfpenny, P.R., Hill, R.G., Horwell, D.C., Hughes, J., Harvis, T.C., Rees, D.C. & Schofield, D. (1988b). Highly selective κ opioid analgesics. Synthesis and structure-agonist relationships of novel N-[(2-aminocyclohexyl)aryl]acetamide and N-[C2-aminocyclohexyl)aryloxy]acetamide derivatives. J. Med. Chem., 31, 831-836.
13. Goldin, A.L. (1995). Voltage-gated sodium channels. In: Ligand-and Voltage-Gated Ion channels, ed. North, R.A. pp 73-122. Boca Raton, FL, CRC Press.
14. Goldin, A.L. & Sumikawa, K. (1992). Preparation of RNA for injection into Xenopus oocytes. Methods Enzymol., 207, 279-297.
15. Grant, A.O., John, J.E., Nesterenko, V.V., Starmer, C.F. & Moorman, J.R. (1996). The role of inactivation in open-channel block of the sodium channel: studies with inactivation-deficient mutant channels. Mol. Pharmacol., 50, 1643-1650.
16. Hille, B. (1977). Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. J. Gen. Physiol., 69, 497-515.
17. Hodgkin, A.L. & Huxley, A.F. (1952). A quantitative description of membrane current and its application to conduction and excitation in nerve. J. Physiol., London, 117, 500-544.
18. Hondeghem, L.M. & Katzung, B.G. (1977). Time-and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels. Biochim. Biophys. Acta, 472, 373-398.
19. 1 subunit of the rat brain sodium channel. Science, 256, 839-842.
20. 2 subunit of brain sodium channels, a transmembrane glycoprotein with a CAM motif. Cell, 83, 433-442.
21. Kallen, R.G., Sheng, Z.-H., Yang, J., Chen, L., Rogart, R.B. & Barchi, R.L. (1990). Primary structure and expression of a sodium channel characteristic of denervated and immature rat skeletal muscle. Neuron, 4, 233-242.
22. + shifts in early ischaemia: mechanisms and relation to changes in impulse propagation. J. Mol. Cell. Cardiol., 19, 34-44.
23. Kontis, K.J. & Goldin, A.L. (1993). Site-directed mutagenesis of the putative pore region of the rat IIA sodium channel. Mol. Pharmacol., 43, 635-644.
24. 2+: voltage and concentration dependence of calcium entry into the pore. J. Gen. Physiol., 88, 321-347.
25. Martin, W.R. (1984). Pharmacology of opioids. Pharmacol. Rev., 35, 285-323.
26. Pugsley, M.K. & Goldin, A.L. (1998). Effects of bisaramil, a novel class I antiarrhythmic agent, on heart, skeletal muscle and brain Na channels. Eur. J. Pharmacol., 342, 93-104.
27. Pugsley, M.K., Penz, W.P. & Walker, M.J.A. (1992b). The cardiovascular actions of the kappa-opioid receptor agonist (-)C1-977. Proc. Can. Fed. Biol. Sci., 35, 220.
28. Pugsley, M.K., Penz, W.P. & Walker, M.J.A. (1993a). Cardiovascular actions of U50,488H and related kappa agonists. Cardiovasc. Drug Rev., 11, 151-164.
29. Pugsley, M.K., Penz, W.P., Walker, M.J.A. & Wong, T.M. (1992a). Antiarrhythmic effects of U50,488H in rats subject to coronary artery occlusion. Eur. J. Pharmacol., 212, 15-19.
30. Pugsley, M.K., Penz, W.P., Walker, M.J.A. & Wong, T.M. (1992c). Cardiovascular actions of the κ-agonist, U50,488H, in the absence and presence of opioid receptor blockade. Br. J. Pharmacol., 105, 521-526.
31. Pugsley, M.K. & Saint, D.A. (1995). Tonic and use-dependent block of sodium currents in isolated cardiac myocytes by bisaramil. Br. J. Pharmacol., 114, 377-382.
32. Pugsley, M.K., Saint, D.A., Hayes, E.S., Kramer, D. & Walker, M.J.A. (1998). Spiradoline - a kappa-receptor agonist with non-opioid antiarrhythmic and electrophysiological properties. J. Cardiovasc. Pharmacol., in press.
33. Pugsley, M.K., Saint, D.A., Penz, W.P. & Walker, M.J.A. (1993b). Electrophysiological and antiarrhythmic actions of the κ agonist PD129290 and its R,R,(+)-enantiomer, PD129289. Br. J. Pharmacol., 110, 1579-1585.
34. Pugsley, M.K., Saint, D.A. & Walker, M.J.A. (1994). An electrophysiological basis for the antiarrhythmic actions of the κ-opioid receptor agonist U50,488H. Eur. J. Pharmacol., 261, 303-309.
35. + channels by local anesthetics. Science, 265, 1724-1728.
36. + channels. Proc. Natl. Acad. Sci. U.S.A., 93, 9270-9275.
37. Sanchez-Chapula, J., Tsuda, Y. & Josephson, I.R. (1983). Voltage-and use-dependent effects of lidocaine on sodium current in rat single ventricular cells. Circ. Res., 52, 557-565.
38. Smith, R.D. & Goldin, A.L. (1998). Functional analysis of the rat I sodium channel in Xenopus oocytes. J. Neurosci., 18, 811 -820.
39. Strichartz, G., Rando, T. & Wang, G.K. (1987). An integrated view of the molecular toxinology of sodium channel gating in excitable cells. Ann. Rev. Neurosci., 10, 237-267.
40. Trimmer, J.S., Cooperman, S.S., Tomiko, S.A., Zhou, J., Crean, S.M., Boyle, M.B., Kallen, R.G., Sheng, Z., Barchi, R.L., Sigworth, F.J., Goodman, R.H., Agnew, W.S. & Mandel, G. (1989). Primary structure and functional expression of a mammalian skeletal muscle sodium channel. Neuron, 3, 33-49.
41. Valenzuela, C., Delpon, E., Franqueza, L., Gay, P., Perez, O., Tamargo, J. & Snyders, D.J. (1996). Class III antiarrhythmic effects of zatebradine. Time-, state-, use-and voltage-dependent block of hKv1.5 channels. Circ., 94, 562-570.
42. Walker, M.L., Wall, R.A. & Walker, M.J.A. (1996). Determination of an arylacetamide antiarrhythmic in rat blood and tissues using reverse-phase high-performance liquid chromatography. J. Chromatography, 675, 257-263.
43. + channel inactivation. Proc. Natl. Acad. Sci. U.S.A., 89, 10910-10914.
44. Wong, T.M., Lee, A.Y.S. & Tai, K.-K. (1990). Effect of drugs interacting with opioid receptors during normal perfusion or ischaemia and reperfusion in the isolated rat heart - an attempt to identify cardiac opioid receptor subtypes(s) involved in arrhythmogenesis. J. Mol. Cell. Cardiol., 22, 1167-1175.
45. Yong, S.L., Abraham, S., Pugsley, M.K., Hayes, E.S., Zolotoy, A.B. & Walker, M.J.A. (1996). SAR evidence that antiarrhythmic activity is unrelated to opioid kappa agonist activity. Br. J. Pharmacol., 119, P35.